Virtu Financial’s Intellia Therapeutics NTLA Stock Holding History

Virtu Financial’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,260	Closed	-$245K	–	2088
2025 Q4	$245K	Buy	+27,260	New	+$375K	0.01%	943
2024 Q4	–	Sell	-20,304	Closed	-$417K	–	1888
2024 Q3	$417K	Buy	+20,304	New	+$468K	0.02%	520
2024 Q2	–	Sell	-29,144	Closed	-$802K	–	1707
2024 Q1	$802K	Buy	+29,144	New	+$810K	0.06%	282
2021 Q4	–	Sell	-5,207	Closed	-$699K	–	2031
2021 Q3	$699K	Sell	5,207 -19,051	-79%	-$2.88M	0.06%	329
2021 Q2	$3.93M	Buy	+24,258	New	+$1.89M	0.38%	24
2020 Q3	–	Sell	-17,656	Closed	-$371K	–	1361
2020 Q2	$371K	Buy	+17,656	New	+$300K	0.04%	474
2018 Q2	–	Sell	-33,149	Closed	-$699K	–	2333
2018 Q1	$699K	Buy	+33,149	New	+$815K	0.04%	526

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial's NTLA Position: Q1 2026 in Review

Virtu Financial sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 27,260 shares — an estimated $245K sold.

Virtu Financial first reported a position in NTLA in Q1 2018 and held it in 7 quarters. The position peaked at $3.93M in Q2 2021. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Virtu Financial reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Virtu Financial sold 27,260 Intellia Therapeutics shares in Q1 2026, an estimated $245K.
Virtu Financial first reported a position in Intellia Therapeutics in Q1 2018 and held it in 7 quarters.
Virtu Financial's Intellia Therapeutics position peaked at $3.93M in Q2 2021.
304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.